The amino-acid sequence of dihydrofolate reductase (7,8-dihydrofolate: NADP + oxidoreductase, EC 1.5.1.4) from S. faecium var Durans strain A is reported, and methionine residues 28 and 50 are shown to be protected by the inhibitor aminopterin from carboxymethylation by iodoacetate which occurs in absence of the inhibitor. Comparison of the sequence with that of the Escherichia coli reductase reveals two domains of considerable homology, one (the N-terminal region) presumably concerned with dihydrofolate and inhibitor binding and the other with dinucleotide binding. No significant sequence homology was found between larger dehydrogenases and the dihydrofolate reductases, which must, therefore, have evolved from a different ancestral protein.Dihydrofolate reductase (7,8-dihydrofolate: NADP+ oxidoreductase, EC 1.5.1.4) is a monomeric, NADPH-linked enzyme and, as isolated from various bacterial and mammalian sources, has a molecular weight in the range of 15,000 to 30,000 (1). The small size is advantageous for structural studies and these should elucidate the mode of binding of inhibitors to the catalytic site. This is of special interest because of the clinical use of such inhibitors; thus, methotrexate has been used in the treatment of neoplastic disease, trimnethoprim for bacterial infections, and pyrimethamine in the treatment of malaria. Comparative structural studies of this enzyme are also of interest because some inhibitors (such as trimethoprim) discriminate efficiently between the bacterial and mammalian reductases (2), and also because bacteria develop resistance which in some cases is due to selectively increased production of one isozyme which is not the predominant species in the sensitive parent strain (3).In this paper we report the complete primary sequence of one of the two dihydrofolate reductases present in a methotrexate-resistant mutant of Streptococcus faecium var Durans (4, 5). This mutant, strain A, was isolated (6) and kindly provided by Dr. D. J. Hutchison of the Sloan Kettering Institute. The enzyme investigated in this study was previously designated by us as the "mutant" enzyme, since it is the predominant form in the mutant organism (5), but it might more properly be called isozyme II since it has less mobility than isozyme I on polyacrylamide gel electrophoresis.Isozyme II, like mammalian dihydrofolate reductases, is capable of reducing folate as well as dihydrofolate although folate reduction is relatively slow. The enzyme predominant in the wild strain is also present in increased levels in the mutant and is designated "wild" enzyme or isozyme I. Like many other bacterial dihydrofolate reductases, it reduces dihydrofolate but not folate. Resistance of strain A to methotrexate is attributed to increased capacity of the organism to reduce the folate supplied in the synthetic medium because of the vastly increased level of isozyme II over that in the sensitive, wild strain.We also report on the position, in the primary sequence of isozyme II, of methionine residues. These re...